PRAC Recommends Suspension of Ulipristal Acetate for Uterine Fibroids

News
Article

The Pharmacovigilance Risk Assessment Committee (PRAC) of EMA has recommended that women stop taking 5-mg ulipristal acetate (Esmya and generic medicines) for the treatment of uterine fibroids while a safety review into potential liver injury risk is performed.

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended that women stop taking 5-mg ulipristal acetate (Esmya and generic medicines) for the treatment of uterine fibroids while a safety review into potential liver injury risk is performed.

In a March 13, 2020 press release, EMA announced it is commencing a review of the treatment at the request of the European Commission as a result of a recent case of liver injury that resulted in a liver transplant. A review of the medicine was performed in 2018, when it was deemed that there was a rare but serious risk of liver injury with ulipristal acetate, and measures were taken to minimize the risk. However, as the latest injury has occurred despite the measures being in place, a new review is being started.

As part of the recommendation, all women taking the medicine for the treatment of uterine fibroids should stop taking the drug immediately and no new patients should be started on the treatment, which will be suspended on a temporary basis while the review is being performed. The recommendation does not affect the single-dose ulipristal acetate emergency contraceptive (ellaOne and other trade names).

Source: EMA

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes